NCT03231475撤回1 期
Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- DLT and MTD of SPH1188-11
研究概览
简要总结
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.
详细描述
Phase I dose escalation study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-70years old, male or female.
- •Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer(NSCLC),Stage IIIBorIV, previous treatment with 1st EGFR-TKI, and/or previous chemotherapy. Regardless of EGFR mutation status.
- •At least one measurable disease according to RECIST 1.
- •Life expectancy of at least 3 months.
- •Eastern Cooperative Oncology Group (ECOG) performance score 0 or
- •Females should be using adequate contraceptive measures from the time of screening until 3 months after discontinuing study treatment, should not be breast feeding and must have a negative pregnancy test 7days prior to start of dosing. Males should be willing to use barrier contraception during the trial and 3 months after discontinuing study treatment.
- •Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
排除标准
- •Treatment with an EGFR-TKI(eg, erlotinib, gefitinib, icotinib) within 7 days or approximately 5x half-life of study entry.
- •Previous treatment with 2nd EGFR-TKI or 3rd EGFR-TKI(eg, afatinib, osimertinib).
- •Any cytotoxic chemotherapy or anticancer drugs within 4 weeks of the first dose of study treatment.
- •Major surgery(excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
- •Radiotherapy within 4 weeks of the first dose of study treatment.
- •Patients currently receiving(or unable to stop use at least 1 week prior to receiving the first dose) medications or herbal supplements known to be potent inhibitors of CYP3A4/CYP2D6, and/or potent inducers of CYP3A4/CYP2D
- •Laboratory values within 7 days of the first dose of study treatment:
- •Absolute neutrophil count<1.5×10^9/L
- •Platelet count <100×10^9/L
- •Haemoglobin<90 g/L
- •Alanine aminotransferase>2.5 times the upper limit of normal(ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases.
- •Aspartate aminotransferase>2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases.
- •Total bilirubin>1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome(unconjugated hyperbilirubinaemia) or liver metastases.
- •Creatinine>1.5 times ULN concurrent with creatinine clearance <50ml/min(measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is>1.5 times ULN.
- •Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events(CTCAE) grade 1 at the time of starting study treatment (except alopecia and prior platinum-therapy related neuropathy)
- •Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
- •Any evidence of severe or uncontrolled systemic diseases, including active bleeding, active infection including hepatitis B(HBsAg+ and HBV-DNA+), hepatitis C and human immunodeficiency virus(HIV).
- •Cardiac criteria: QTc>480msec. LVEF<50%. Any clinically important abnormalities in rhythm, any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family in first degree relatives or any concomitant medication known to prolong the QT interval.
- •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- •Idiopathic pulmonary fibrosis.
- •Chronic gastrointestinal diseases, characterized by diarrhea.
- •Inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of SPH1188-
- •History of Keratitis, ulcerative keratitis, severe xerophthalmia.
- •Previous or concomitant malignancies at other sites, except effectively treated nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured.
- •History of neurological or mental disorders, including epilepsy or dementia.
- •Allergy to the test drug or any excipient of the product.
- •Participate in other drug clinical trials within 4 weeks of the first dose of study treatment.
- •Receiving any other anti-tumor therapy.
- •Women who are breast feeding or pregnant.
- •Judgment by the investigator that the patient should not participate in the study.
研究组 & 干预措施
SPH1188-11
Experimental
SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
干预措施: SPH1188-11 (Drug)
结局指标
主要结局
DLT and MTD of SPH1188-11
时间窗: 28 days
Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH1188-11, to find DLT and MTD
次要结局
- Cmax of SPH1188-11(28 days)
- Tmax of SPH1188-11(28 days)
- ORR of SPH1188-11(52 weeks)
- PFS of SPH1188-11(52 weeks)
- DCR of SPH1188-11(52 weeks)
- AUC of SPH1188-11(28 days)
- T1/2 of SPH1188-11(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)Non-small Cell Lung CancerNCT05926180Dizal Pharmaceuticals25
已完成
1 期
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerNonsmall Cell Lung CancerNCT03450330Dizal Pharmaceuticals10
已完成
1 期
AZD9291 First Time In Patients Ascending Dose StudyAdvanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung CancerNCT01802632AstraZeneca603
终止
1 期
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaNon-small Cell Lung Cancer AdenocarcinomaNCT03696212Arrys Therapeutics18
终止
1 期
Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the LungLung Cancer Squamous CellNCT04496674German Cancer Research Center3